Catalent (Catalent) Change In Working Capital : $6 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Catalent Change In Working Capital?

Catalent's change in working capital for the quarter that ended in Mar. 2024 was $-101 Mil.

Catalent's change in working capital for the fiscal year that ended in Jun. 2023 was $-288 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Catalent Change In Working Capital Historical Data

The historical data trend for Catalent's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent Change In Working Capital Chart

Catalent Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Working Capital

Get a 7-Day Free Trial

-160.00

-122.00

-432.00

-587.00

-288.00

Catalent Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															-120.00	113.00	-107.00	101.00	-101.00

Catalent Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $6 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Catalent Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Catalent's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalent (Catalent) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (NYSE:CTLT) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

0C8:Germany 0C8:Germany

Address

14 Schoolhouse Road, Somerset, NJ, USA, 08873

Website

https://www.catalent.com

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

Executives

David Mcerlane	officer: Group President, Biologics	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Steven Barg	director	ELLIOTT MANAGEMENT CORPORATION, 40 WEST 57TH STREET, NEW YORK NY 10019
Michelle R Ryan	director	214 PARK BLVD S, VENICE FL 34285
John J Greisch	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephanie Okey	director	C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Frank A Damelio	director	C/O PFIZER INC., 235 EAST 42ND ST., NEW YORK NY 10017
Aristippos Gennadios	officer: See Remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Thomas W Hawkeswood	officer: Pres. Pharma Prod Delivery Div	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Patricia Hunt	officer: Pres. Consumer Health Div	C/O CATALENT, 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricky Hopson	officer: VP, Chief Accounting Officer	CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Lorenzo Carletti	officer: SVP Global Ops Small Molecule	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricardo Pravda	officer: SVP, Human Resources	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Alessandro Maselli	officer: See remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Charles Lickfold	officer: SVP, CIO	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Scott Gunther	officer: See Remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873